CN102885844A - Application of Houttuynoid B in medicine for treating tongue cancer - Google Patents

Application of Houttuynoid B in medicine for treating tongue cancer Download PDF

Info

Publication number
CN102885844A
CN102885844A CN2012104175006A CN201210417500A CN102885844A CN 102885844 A CN102885844 A CN 102885844A CN 2012104175006 A CN2012104175006 A CN 2012104175006A CN 201210417500 A CN201210417500 A CN 201210417500A CN 102885844 A CN102885844 A CN 102885844A
Authority
CN
China
Prior art keywords
houttuynoid
medicine
tongue cancer
application
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012104175006A
Other languages
Chinese (zh)
Other versions
CN102885844B (en
Inventor
俞骁
施桦
吴俊华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qidong Tianfen Electric Tool Technology Innovation Center
Original Assignee
吴俊华
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吴俊华 filed Critical 吴俊华
Priority to CN201210417500.6A priority Critical patent/CN102885844B/en
Publication of CN102885844A publication Critical patent/CN102885844A/en
Application granted granted Critical
Publication of CN102885844B publication Critical patent/CN102885844B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses an application of Houttuynoid B in preparation for a medicine for treating tongue cancer, belonging to the technical field of medicine new applications. According to the invention, in-vitro MTT (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) anti-tumour activity evaluation finds that Houttuynoid B also has a remarkable inhibition effect on the growths of human tongue cancer cell strains Tca8113 and T6. Thus, Houttuynoid B can be used for preparing the medicine for treating the tongue cancer, and has a good development and application prospect. The application of the Houttuynoid B in preparation for the medicine for treating the tongue cancer is initially disclosed; and Houttuynoid B has a brand new framework type and an unexpected inhibition activity on tongue cancer cells.

Description

The application of Houttuynoid B in treatment carcinoma of tongue medicine
Technical field
The present invention relates to the new purposes of compound H outtuynoid B, relate in particular to the application of Houttuynoid B in the anti-carcinoma of tongue medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid B that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid B that the present invention relates in preparation treatment carcinoma of tongue medicine, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of tongue obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid B in the anti-carcinoma of tongue medicine of preparation, and the structural formula of Houttuynoid B is shown in formula I:
Figure BDA0000231838521
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid B also has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6, suppresses the IC of this 2 strain Growth of Cells 50Value is respectively 2.13 ± 0.21 μ M and 3.19 ± 0.14 μ M.Therefore, Houttuynoid B can for the preparation of anti-carcinoma of tongue medicine, have good development prospect.
The purposes of the Houttuynoid B that the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of tongue obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid B involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid B tablet involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid B capsule involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid B to the growth inhibited effect of people's Human Tongue Carcinoma Lines strain
1. method: the cell that is in the growth logarithmic (log) phase: people's Human Tongue Carcinoma Lines strain Tca8113 and T6(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10 4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO 2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD Drug treating/ Δ OD Blank* 100.
2. result: Houttuynoid B has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6.This chemical compound suppresses the IC of people Human Tongue Carcinoma Lines strain Tca8113 and T6 growth 50Value is respectively: 2.13 ± 0.21 μ M and 3.19 ± 0.14 μ M.
Shown by above-described embodiment, Houttuynoid B of the present invention has good inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6.Prove thus, it is active that Houttuynoid B of the present invention has anti-carcinoma of tongue, can be for the preparation of anti-carcinoma of tongue medicine.

Claims (1)

1.Houttuynoid the application of B in treatment carcinoma of tongue medicine, described compound H outtuynoid B structure as Formula IShown in:
Figure 2012104175006100001DEST_PATH_IMAGE001
Formula I.
CN201210417500.6A 2012-10-27 2012-10-27 Application of Houttuynoid B in medicine for treating tongue cancer Active CN102885844B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210417500.6A CN102885844B (en) 2012-10-27 2012-10-27 Application of Houttuynoid B in medicine for treating tongue cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210417500.6A CN102885844B (en) 2012-10-27 2012-10-27 Application of Houttuynoid B in medicine for treating tongue cancer

Publications (2)

Publication Number Publication Date
CN102885844A true CN102885844A (en) 2013-01-23
CN102885844B CN102885844B (en) 2014-04-16

Family

ID=47529663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210417500.6A Active CN102885844B (en) 2012-10-27 2012-10-27 Application of Houttuynoid B in medicine for treating tongue cancer

Country Status (1)

Country Link
CN (1) CN102885844B (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHAO-DAN CHEN,等: "Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 *

Also Published As

Publication number Publication date
CN102885844B (en) 2014-04-16

Similar Documents

Publication Publication Date Title
CN102885844B (en) Application of Houttuynoid B in medicine for treating tongue cancer
CN102872076B (en) Application of Houttuynoid A in drugs for treating tongue cancer
CN102861059B (en) Application of Houttuynoid D in pancreatic cancer treatment medicine
CN102861070B (en) Application of Houttuynoid E in medicine for treating tongue cancer
CN102872148B (en) Application of Houttuynoid D in medicament for treating tongue cancer
CN102861065A (en) Application of Houttuynoid E in medicine for treating gastric cancer
CN102872150B (en) Application of Houttuynoid B in medicament for treating prostatic cancer
CN102872095B (en) Application of Houttuynoid E in medicine for treating ileocecum cancer
CN102861050A (en) Application of Houttuynoid A in medicine for treating pancreatic cancer
CN102872134B (en) Application of Houttuynoid D in drug for treating laryngocarcinoma
CN102872109B (en) Application of Houttuynoid A in medicament for treating prostate cancer
CN102861073A (en) Application of Houttuynoid A in medicine for treating colorectal cancer
CN102861099A (en) Application of Houttuynoid D in medicine for treating endometrial cancer
CN102872103A (en) Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma
CN102861048A (en) Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma
CN102861071A (en) Application of Houttuynoid A in medicine for treating gastric cancer
CN102861075A (en) Application of Houttuynoid B in medicine for treating gastric cancer
CN102861080A (en) Application of Houttuynoid C in medicine for treating nasopharynx cancer
CN102895249A (en) Application of Houttuynoid E to medicament for treating prostatic carcinoma
CN102872151A (en) Application of Houttuynoid B in medicament for treating nasopharyngeal cancer
CN102872093A (en) Application of Houttuynoid E in medicine for treating pancreatic cancer
CN102861069A (en) Application of Houttuynoid B in medicine for treating laryngocarcinoma
CN102861064A (en) Application of Houttuynoid E in medicine for treating laryngocarcinoma
CN102872139A (en) Application of Houttuynoid C in drug for treating tongue cancer
CN102872088A (en) Application of Houttuynoid D in medicines for treating nasopharyngeal carcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION

Free format text: FORMER OWNER: WU JUNHUA

Effective date: 20141126

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20141126

Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building

Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center

Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing

Patentee before: Wu Junhua